Related Experiment Videos
[Clinical studies on cefdinir granules in pediatric field]
1Department of Pediatrics, Tokyo Ebara Municipal Hospital.
Insights
Cefdinir (CFDN) granules, an oral antibiotic for children, demonstrated a dose-dependent plasma level and high efficacy (97.6%) in treating pediatric infections. Bacterial eradication was 82.8% with no significant side effects observed.
Area of Science:
- Pediatric Infectious Diseases
- Pharmacokinetics and Pharmacodynamics
- Antimicrobial Therapy
Background:
- Cefdinir (CFDN) is a novel oral antibiotic.
- Pediatric infections require effective and safe antimicrobial agents.
Purpose of the Study:
- To evaluate the pharmacokinetics, clinical efficacy, and safety of Cefdinir (CFDN) granules in children.
- To assess the impact of different dosages on plasma levels and urinary excretion.
- To determine the bacterial eradication rates and overall clinical outcomes.
Main Methods:
- Cefdinir granules were administered to pediatric patients at doses of 3-6 mg/kg to assess plasma levels and urinary excretion.
- A total of 42 children with upper/lower airway or urinary tract infections received daily doses of 9.0-20.7 mg/kg in divided portions.
- Clinical efficacy, bacterial eradication, and adverse events were monitored.
Main Results:
- Plasma levels of CFDN showed a dose-response relationship, peaking at 2-3 hours post-administration.
- 8-hour urinary excretion ranged from 10.3-17.4% of the administered dose.
- An overall clinical efficacy rate of 97.6% was achieved, with a bacterial eradication rate of 82.8%.
- No significant side effects were reported, with only minor laboratory abnormalities in isolated cases.
Conclusions:
- Cefdinir (CFDN) granules exhibit favorable pharmacokinetic properties and high clinical efficacy in pediatric patients.
- The antibiotic is well-tolerated, demonstrating a good safety profile for treating common childhood infections.
- Cefdinir represents a promising therapeutic option for pediatric bacterial infections.
Abstract:
Cefdinir (CFDN, FK482) granules, a new oral antibiotic for children, were given to children with infections. The results obtained are summarized as follows. 1. The plasma level of CFDN peaked at 0.38-0.88 microgram/ml in 2-3 hours after administration of the drug at a dose of 3 mg/kg. Meanwhile, the plasma level peaked at 1.85 micrograms/ml in 3 hours after administration of 6 mg/kg. The plasma level was higher in the 6 mg/kg group than that in the 3 mg/kg group, thus a dose response was clearly observed. 2. The 8 hour urinary excretion accounted for 10.3-17.4% of administered amount of the drug in children with 3-6 mg/kg dosage. 3. CFDN granules were administered to a total of 42 children with upper or lower airway infections or with urinary tract infections at daily doses of 9.0-20.7 mg/kg in 3 divided portions. The clinical efficacy was "excellent" in 28 patients, "good" in 13, and "fair" in 1, hence an efficacy rate of 97.6% was obtained. 4. Bacteria identified from various diseases were 29 strains of 9 species, and the eradication rate was 82.8%. 5. No. side effects were noted in any of the children. Laboratory test results showed an abnormality in 1 case each with a rise of platelet count and eosinophilia.